A Look at the Comorbidity of Eating Disorders and Addiction
Dr. Elizabeth Wassenaar is featured in this Psychiatric Times article examining the comorbidity of eating disorders and addiction and the potential impact and complexity of using GLP-1 agonist medications in treatment. In the article, Dr. Wassenaar shares concerns about using GLP-1As and their impact on the eating disorder community:
"GLP-1 receptor agonists work in the brain to suppress appetite and increase feelings of fullness, which is how they act for individuals who take them to manage their type 2 diabetes. We are beginning to notice patients who are vulnerable to disordered eating and/or relapse of their eating disorder following the initiation of GLP-1 receptor agonist medications."
Read the Full Article from Psychiatric Times
Psychiatric Times® sat down with Elizabeth Wassenaar, MD, MS, CEDS-S, DFAPA, regional medical director of the Eating Recovery Center in Denver, Colorado, to discuss the comorbidity of eating disorders and addiction, as well as the effects of semaglutide and other GLP-1 agonists on patients with eating disorders.
